Johnson & Johnson (NYSE:JNJ) Shares Sold by SOA Wealth Advisors LLC.

SOA Wealth Advisors LLC. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 10.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,420 shares of the company’s stock after selling 903 shares during the period. SOA Wealth Advisors LLC.’s holdings in Johnson & Johnson were worth $1,073,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of JNJ. Wealth Group Ltd. acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $213,000. Swedbank AB raised its stake in Johnson & Johnson by 5.3% during the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after buying an additional 111,570 shares in the last quarter. Catalina Capital Group LLC lifted its holdings in Johnson & Johnson by 22.2% during the 3rd quarter. Catalina Capital Group LLC now owns 8,098 shares of the company’s stock worth $1,312,000 after buying an additional 1,473 shares during the last quarter. Wisconsin Capital Management LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $203,000. Finally, Radnor Capital Management LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $9,318,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.3 %

NYSE:JNJ opened at $165.66 on Friday. The stock has a fifty day simple moving average of $152.52 and a 200 day simple moving average of $156.25. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $398.85 billion, a price-to-earnings ratio of 24.91, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the previous year, the company posted $2.29 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 2.99%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Barclays raised their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. Citigroup lowered their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.